A
Adam Torbicki
Researcher at Medical University of Warsaw
Publications - 349
Citations - 104144
Adam Torbicki is an academic researcher from Medical University of Warsaw. The author has contributed to research in topics: Pulmonary hypertension & Pulmonary embolism. The author has an hindex of 83, co-authored 334 publications receiving 91421 citations. Previous affiliations of Adam Torbicki include Erasmus University Rotterdam & New York Academy of Medicine.
Papers
More filters
Journal ArticleDOI
Detection of patients at risk for recurrence of atrial fibrillation after successful electrical cardioversion by signal-averaged P-wave ECG
Grzegorz Opolski,Piotr Ścisło,Jolanta Stanislawska,Górecki A,Roman Steckiewicz,Adam Torbicki +5 more
TL;DR: It is suggested that signal-averaged ECG of P-wave may be helpful for identification of patients with recurrence of atrial fibrillation after successful direct-current electrical cardioversion of chronic atrialfibrillation.
Journal ArticleDOI
Prognostic Significance of Right Heart Thrombi in Patients With Acute Symptomatic Pulmonary Embolism: Systematic Review and Meta-analysis.
Deisy Barrios,Vladimir Rosa-Salazar,Raquel Morillo,Rosa Nieto,Sara Fernández,José Luis Zamorano,Manuel Monreal,Adam Torbicki,Roger D. Yusen,David Jiménez +9 more
TL;DR: In patients diagnosed with acute PE, concomitant RHT were significantly associated with an increased risk of death within 30 days of PE diagnosis.
Journal ArticleDOI
Summary of recommendations for the haemodynamic and angiographic assessment of the pulmonary circulation. Joint statement of the Polish Cardiac Society's Working Group on Pulmonary Circulation and Association of Cardiovascular Interventions.
Marcin Kurzyna,Aleksander Araszkiewicz,Piotr Błaszczak,Marek Grabka,Michał Hawranek,Grzegorz Kopeć,Ewa Mroczek,Marian Zembala,Adam Torbicki,Andrzej Ochała +9 more
TL;DR: Recommendations are developed to standardise guidelines for RHC procedure, acute vasoreactivity testing and pulmonary angiography at cardiac wards and haemodynamic laboratories in Poland due to the dynamic growth in the number of patients diagnosed with and treated for PH.
Journal ArticleDOI
Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
Richard N. Channick,Marion Delcroix,Hossein Ardeschir Ghofrani,Hossein Ardeschir Ghofrani,Elke Hunsche,Pavel Jansa,Franck-Olivier Le Brun,Sanjay Mehta,Tomás Pulido,Lewis J. Rubin,B.K.S. Sastry,Gérald Simonneau,Olivier Sitbon,Rogério Souza,Adam Torbicki,Nazzareno Galiè +15 more
TL;DR: Macitentan 10 mg significantly reduced the risk and rate of all-cause hospitalization, which was driven by reductions in the riskand rate of PAH-related hospitalization.
Journal ArticleDOI
The role of echocardiography in the diagnosis and management of patients with pulmonary hypertension
Gilbert Habib,Adam Torbicki +1 more
TL;DR: Echocardiographic assessment as part of a goal-oriented approach to therapy is essential for the effective management of PH patients and is recommended 3−4 months after initiation of, or a change in, therapy.